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The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors 
which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in 
patients with positive tumour hormone receptor status. The patients with early disease progression during 
first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to 
first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate 
analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval 
(p = .001; p < .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p < .0001; p 
= 0.0001) and an administration of maintenance hormonal therapy (p < .0001; p = .001). The major impact 
obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that 
this strategy should be recommended in patients with an ER or PgR positive tumour. 
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INTRODUCTION 
Breast cancer is the most common cancer among 
women in the USA and Western Europe. World 
incidence was 1  050  000 cases during the year 2000 
with a mortality rate of 373  000 [1]. Despite earlier 
diagnosis and improvement in adjuvant therapies 
some patients will present metastatic recurrence. Then, 
the disease is incurable and the median of survival is 
18 to 24 months [2-3]. The use of systemic therapies 
such as hormonal therapy, chemotherapy or new 
biological treatment is to reduce tumour masses, 
improve survival and preserve quality of life. 
Whatever the initial efficacy of the treatment 
undertaken in metastatic setting, almost every patient 
will relapse. The main goal is to improve progression 
free survival (PFS). To achieve this, the type of 
chemotherapy, the optimal duration of chemotherapy, 
the benefit of maintenance chemotherapy, the benefit 
of maintenance hormonal treatment are debatable. The 
present study was conducted to identify the factors 
which influence progression-free survival after the 
first line of chemotherapy. Among them, the present 
study focuses on the impact of hormonal maintenance 
therapy and constitutes the largest retrospective study 
on this subject. 
PATIENTS AND METHODS 
Study population 
This study included 934 patients treated for 
metastatic breast cancer in 4 French cancer centres. The 
diagnosis of metastasis was made between 1992 and 
2002. A total of 772 patients received first-line 
chemotherapy [4]. Because the present analysis focuses 
on the impact of hormonal treatment beyond first line 
chemotherapy, we included only patients with 
positive tumour hormonal receptor status established 
on the primary tumour. When early disease 
progression occurs at first chemotherapy response 
assessment or within 3 months after the first cycle of 
chemotherapy in metastatic disease, one can consider 
that it is a failure of chemotherapy. It will not be 
relevant to search in this subset for factors which 
influence progression-free survival (PFS). Those cases 
were excluded from the present analysis. In total, 560 Int. J. Med. Sci. 2008, 5 
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patients were studied to detect predictive factors to the 
duration of PFS after first-line chemotherapy and 
among those factors the impact of hormonal treatment 
given as maintenance therapy was analysed. 
Statistical analysis 
The duration of PFS is defined as the time from 
the beginning of first line chemotherapy treatment to 
the date of progressive disease or death. Metastatic 
survival is defined as the time from the diagnosis of a 
metastasis to date of death or last follow-up. PFS, 
metastatic and overall survival were estimated using 
the Kaplan-Meier method. Comparisons were 
performed using the log-rank test. Proportional 
hazards Cox model was used to identify which factors 
could influence the duration of PFS. Each significant 
variable in univariate analysis was included in 
multivariate analysis. The adjusted Hazard Ratio 
(ad-HR) was provided for each significant variable. 
The following variables were included in the Cox 
model: menopausal status (pre- versus post- 
menopause); nodal involvement of the primary 
tumour (positive versus negative); hormonal receptor 
(HR) status (positive if estrogen receptors and/or 
progesterone receptors are positive versus negative); 
initial surgery (partial versus radical mastectomy); 
adjuvant chemotherapy (yes versus no); adjuvant 
hormonal therapy (yes versus no); complementary 
radiotherapy (yes versus no); disease free interval 
(DFI) between the date of diagnosis of breast cancer 
and the date of first diagnosis of metastatic disease 
(under or above two years); metastatic site (bone 
and/or node and/or skin and/or pulmonary versus 
liver); number of metastatic sites  (single versus 
multiple); type of first-line chemotherapy 
(anthracycline- and/or taxane-containing regimen 
versus other); previous line of hormonotherapy 
administered in metastatic setting before the first-line 
chemotherapy (no versus yes); best response to 
first-line chemotherapy (complete (CR) or partial 
response (PR) versus stable disease (SD) defined 
according to recist criteria); maintenance hormonal 
therapy (yes versus no). 
RESULTS 
A total of 560 patients were studied and table 1 
describes patients’ characteristics. Maintenance 
hormonal therapy was given alone after chemotherapy 
in 308 patients. The hormonal treatment was tamoxifen 
(94), aromatase inhibitors (153), fulvestran (47) and 
megesterol acetate (14). The median duration of first 
line chemotherapy was 4.4 months (ranges: 3 – 9.7). 
The factors identified to improve the duration of PFS 
in multivariate analysis were: number of metastatic 
sites (p = .01), metastatic sites (p = .02), Disease free 
interval (p = .001), previous hormonal therapy (p = 
.03), response to first line chemotherapy (p < .0001) 
and an administration of maintenance hormonal 
therapy (p < .0001). The factors related to an increase of 
OS duration in multivariate analysis were: number of 
metastatic sites (p = .01), metastatic sites (p = .04), 
Disease free interval (p < .0001), response to first line 
chemotherapy (p = 0.0001) and an administration of 
maintenance hormonal therapy (p = .001).   
Table 1. Patients characteristics. 
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Tables 2 and 3 list the significant predictive 
factors for the duration of PFS and OS after first-line 
chemotherapy. Figures 1 and 2 show the patients’ PFS 
and OS from the first line of chemotherapy according 
to maintenance hormonal status. 
 
Table 2. Significant predictive factors for PFS duration after a first line chemotherapy. 
 
Table 3. Predictive factors for OS duration after a first line chemotherapy. 
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Figure 1. Progression free survival in first-line chemotherapy according to maintenance hormonal treatment status. 
 
 
 
Figure 2. Patient overall survival (OS) from the first line chemotherapy according to maintenance hormonal treatment status. 
 
DISCUSSION 
The search for prognostic and predictive factors 
that could influence the survival of patients treated for 
metastatic breast cancer has already been the subject of 
several studies. It seems that 2 components in the 
natural outcome of tumours must be considered. The 
first category is related to the primary characteristics 
such as initial histological grade, hormonal receptor 
status. The second category is linked to the metastatic 
characteristics: proliferation index reflected by the 
length of disease-free interval, type and number of 
metastatic sites involved. On the other hand, some 
prognostic factors are linked to the treatments 
undertaken, stressing their impact on the natural 
outcome of the disease: type of hormonotherapy, type 
of chemotherapy, type of response achieved by 
treatment [5-12]. The impact of some factors remains 
debatable, such the duration of treatment. The optimal 
duration of chemotherapy in patients who respond or 
have stable disease is not identified. In 1987, Coates 
compared continuous chemotherapy (until 
progression or toxicity) versus intermittent 
chemotherapy (stop after three cycles and re-treatment 
at the time of disease progression) [13].  Patients 
receiving continuous therapy had superior response 
rates, time to progression, and quality-of-life scores, 
but no improvement in survival was observed. A Int. J. Med. Sci. 2008, 5 
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similar trial conducted by the Piedmont Oncology 
Association randomly assigned patients who had 
responding or stable disease after six cycles of CAF to 
either CMF or observation. In the observation subset, 
CMF was given when disease progression occurred 
[14]. Time to progression was three times longer in 
patients under continuous therapy than for those with 
interrupted treatment (9.4 vs. 3.2 months, 
respectively), but overall survival in both groups was 
similar. Falkson et al randomly assigned 141 patients 
whose measurable disease showed a complete 
response after six cycles of CAF to receive either 
maintenance chemo-hormonal therapy or observation 
[15]. Time to disease progression was 19 months in 
patients who received the maintenance treatment 
versus 8 months in patients under observation but 
again the overall survival curves were similar in both 
groups. The French Epirubicin Study Group study, 
Gregory trial and Nooij study lead to the same results 
when they compared interrupted with prolonged 
chemotherapy regimen: continuous therapy tends to 
improve duration of response and progression-free 
survival without a significative impact on overall 
survival [16-18]. In total, a chemotherapy holiday is 
associated with a shorter time-to-progression but no 
adverse effect on survival. While in some studies, 
continuous chemotherapy seemed not to affect the 
quality of life [13, 18], several studies showed 
increased rates of adverse effects [14, 15, 17]. 
Definitively, the major limit to the use of prolonged 
regimens of chemotherapy is related to their toxicity, 
all the more so as they are cumulative (cardiac toxicity 
of anthracyclins, neurologic toxicity of taxanes, 
haematological cumulative toxicities with any 
chemotherapy…). The proposition to give hormonal 
treatment to prolong therapy in hormonal-positive 
tumors is another possible option. In the literature, 
data focused on this strategy are rare. Only one 
prospective randomised study published by Kloke et 
al in 1999 is available [19]. In this phase-III trial, 90 
patients with a disease controlled after 6 cycles of 
anthracyclin- and ifosfamide-containing regimen were 
randomised to receive or not maintenance therapy by 
medroxyprogesterone acetate. A longer median 
time-to-progression was reported among patients who 
were treated by maintenance hormonotherapy (4. 9 
versus 3. 7 months; p = 0. 02). Two retrospective 
studies found hormonal maintenance therapy as a 
significant factor among several prognostic factors for 
disease-free survival and overall survival after first 
line chemotherapy. In 1997, Berruti et al analysed the 
factors influencing response rate and overall survival 
among 207 patients treated by epirubicin, followed or 
not by maintenance hormonotherapy [20]. The patients 
who received maintenance hormonotherapy survived 
significantly longer than those submitted to 
observation in uni- and multivariate analysis. The 
author concluded that “the positive impact of 
maintenance hormonal therapy is impressive and 
deserves confirmation in randomized studies”. 
Montemurro et al studied 109 patients receiving 
high-dose chemotherapy and analysed the factors 
which improve its efficacy [21]. Maintenance hormonal 
therapy appeared to be a significant factor in 
multivariate analysis. The maintenance hormonal 
treatment improved the progression-free survival from 
19, 2 to 31, 1 months (p = 0, 022).   
The influence of the type of response achieved by 
first line chemotherapy is well established [11]. 
Strikingly, in the present study, hormonal treatment 
administered after response or stabilisation with 
first-line chemotherapy seemed related to a better 
outcome with 7.8 to 16.3 months for the duration of 
PFS (p < 0. 0001) and from 30 to 48.1 months for the 
overall duration of metastatic survival (p < 0. 0001). 
This benefit was observed independently of the type of 
response achieved by first line chemotherapy. One can 
object that the choice of patient/tumour characteristics 
for who would or would not receive the maintenance 
hormonal therapy was not random, or controlled in 
any way. This may have led to a selection of better 
prognosis patients. We cannot know whether we are 
observing natural history or impacting it in such a trial. 
Nevertheless the major impact obtained by 
maintenance hormonal treatment after the first line 
chemotherapy might indicate that this strategy should 
b e  r e c o m m e n d e d  i n  p a t i e n t s  w i t h  a n  E R  o r  P g R  
positive tumour. Based on the amplitude of the benefit 
observed, it may be ethically debatable to conduct a 
prospective randomized study. Moreover, randomized 
trials which assess the benefit of a new chemotherapy 
regimen should allow the possibility to give 
maintenance hormonal treatment.   
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